Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: LINC01852 inhibits the tumorigenesis and chemoresistance in colorectal cancer by suppressing SRSF5-mediated alternative splicing of PKM

Fig. 2

LINC01852 inhibits CRC cell growth in vitro and in vivo. (A) qRT-PCR was performed to measure LINC01852 expression levels in different CRC cell lines and NCM460 cells. (B, C) The subcellular distribution of LINC01852 in CRC cells was determined using RNA-FISH (B) and qRT-PCR (C). Blue indicates DAPI staining of nuclei, and red (Cy3) indicates LINC01852 or 18S rRNA. (D) qRT-PCR validation of LINC01852 expression levels in CRC cells transfected with the LINC01852 overexpression plasmid or the LINC01852-specific ASOs. (E, F) The effects of LINC01852 on cell proliferation (E) and colony formation abilities (F). (G) The effect of LINC01852 on CRC tumor growth in vivo was evaluated using a xenograft model. Tumor volumes were recorded at the indicated times to construct a growth curve and tumor weights were measured after mouse sacrifice (n = 5). *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page

Molecular Cancer

ISSN: 1476-4598